Incyte Announces New Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa

 

• Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS).
  
  
• Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100.
  
  
• Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54.
  
  
• The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated.

https://www.businesswire.com/news/home/20260328441699/en/Incyte-Announces-New-Positive-54-Week-Late-Breaking-Data-for-Povorcitinib-in-Hidradenitis-Suppurativa-at-the-2026-American-Academy-of-Dermatology-AAD-Annual-Meeting